Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Famotidine  COVID-19 treatment studies for Famotidine  C19 studies: Famotidine  Famotidine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 61% Improvement Relative Risk Death/intubation 50% c19early.org/fm Mather et al. Famotidine for COVID-19 Prophylaxis Is prophylaxis with famotidine beneficial for COVID-19? PSM retrospective 772 patients in the USA Lower mortality (p=0.004) and death/intubation (p=0.003) Mather et al., American J. Gastroenterology, doi:10.14309/ajg.0000000000000832 Favors famotidine Favors control

Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19

Mather et al., American Journal of Gastroenterology, doi:10.14309/ajg.0000000000000832
Mather et al., Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19, American Journal of Gastroenterology, doi:10.14309/ajg.0000000000000832
Aug 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
PSM retrospective 878 hospitalized patients in the USA, 83 with existing famotidine use, showing significantly lower mortality with treatment.
risk of death, 61.4% lower, HR 0.39, p = 0.004, treatment 83, control 689, propensity score matching, Cox proportional hazards.
risk of death/intubation, 50.5% lower, HR 0.49, p = 0.003, treatment 83, control 689, propensity score matching, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mather et al., 26 Aug 2020, retrospective, USA, peer-reviewed, 3 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFamotidineAll
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19
MS. Jeffrey F Mather, PhD Richard L Seip, MD Raymond G Mckay
American Journal of Gastroenterology, doi:10.14309/ajg.0000000000000832
INTRODUCTION: To compare outcomes in patients hospitalized with coronavirus (COVID-19) receiving famotidine therapy with those not receiving famotidine.
Study Highlights WHAT IS KNOWN? 3 Despite multiple trials that are currently underway to investigate the safety and efficacy of a large number of possible therapeutic agents, no drug to date has been shown to reduce COVID-19 mortality. 3 It has been postulated that famotidine's effect is achieved via its antagonism or inverse agonism of the histamine-2 receptor, inferring that the SARS-CoV-2 infection that results in COVID-19 is at least partially mediated by pathological histamine release. COVID-19 Mather et al.
References
Anand, Ziebuhr, Wadhwani, Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs, Science
Borrell, New York clinical trial quietly tests heartburn remedy against coronavirus
Bourinbaiar, Fruhstorfer, The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: Identification of a new class of antiviral agents, Life Sci
Burde, Seifert, Buschauer, Histamine inhibits activation of human neutrophils and HL-60 leukemic cells via H2-receptors, Naunyn Schmiedebergs Arch Pharmacol
Caughey, Raymond, Wolters, Angiotensin II generation by mast cell alpha-and beta-chymases, Biochim Biophys Acta
Eliezer, Hautefort, Hamel, Sudden and complete olfactory loss of function as a possible symptom of COVID-19, JAMA Otolaryngol Head Neck Surg
Ezeamuzie, Philips, Histamine, 2) receptors mediate the inhibitory effect of histamine on human eosinophil degranulation, Br J Pharmacol
Flamand, Plante, Picard, Histamine-induced inhibition of leukotriene biosynthesis in human neutrophils: Involvement of the H2 receptor and cAMP, Br J Pharmacol
Freedberg, Conigliaro, Wang, Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study, Gastroenterology, doi:10.1053/j.gastro.2020.05.053
Giacomelli, Pezzati, Conti, Self-reported olfactory and taste disorders in SARS-CoV-2 patients: A cross-sectional study, Clin Infect Dis
Janowitz, Gablenz, Pattinson, Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: A case series, Gut
Kritas, Ronconi, Caraffa, Mast cells contribute to coronavirus-induced inflammation: New anti-inflammatory strategy, J Biol Regul Homeost Agents
Malone, Tisdall, Smith, COVID-19: famotidine, histamine, mast cells, and mechanisms, Preprint Res Sq, doi:10.21203/rs.3.rs-30934/v2
Marshall, Portales-Cervantes, Leong, Mast cell responses to viruses and pathogen products, Int J Mol Sci
Metcalfe, Baram, Mekori, Mast cells, Physiol Rev
Mukai, Tsai, Saito, Mast cells as sources of cytokines, chemokines, and growth factors, Immunol Rev
Rabier, Damon, Chanez, Inhibition by histamine of plateletactivating-factor-induced neutrophil chemotaxis in bronchial asthma, Int Arch Allergy Appl Immunol
Theoharides, Alysandratos, Angelidou, Mast cells and inflammation, Biochim Biophys Acta
Tian, Hu, Niu, Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer, J Thorac Oncol
Wadee, Anderson, Sher, In vitro effects of histamine on migration, Int Arch Allergy Appl Immunol
Wu, Liu, Yang, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm Sin B
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit